Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 10/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17781897 | 0.92 | AGTR2 (0.66) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL4183361 | 0.92 | AGTR2 (0.68) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL6823393 | 0.91 | AGTR2 (0.71) | AGTR2 | |
| SCHEMBL4183014 | 0.91 | AGTR2 (0.64) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL4192598 | 0.91 | AGTR2 (0.64) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL4192674 | 0.89 | AGTR2 (0.64) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL17781906 | 0.89 | AGTR2 (0.68) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL4190385 | 0.88 | AGTR2 (0.67) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL4187910 | 0.87 | AGTR2 (0.69) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL17781911 | 0.86 | AGTR2 (0.66) | AGTR2CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869009-B1 | NEW BICYCLIC ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2016-06-01 | — | — | EP | claimed |
| EP-1869009-B1 | NEW BICYCLIC ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2016-06-01 | — | — | EP | disclosed |
| US-8357710-B2 | Bicyclic angiotensin II agonists | VICORE PHARMA AB (SE) | 2013-01-22 | — | — | US | disclosed |
| US-20090069382-A1 | Bicyclic Angiotensin II Agonists | VICORE PHARMA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069382-A1 | Bicyclic Angiotensin II Agonists | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885CYP2C9 1592/4885CYP2B6 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.